Clinical Trial Update: Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers [Phase 1]

View source ↗

Summary

This clinical trial update summarizes the Phase 1 study of STRO-002, an anti-Folate Receptor Alpha antibody-drug conjugate, in ovarian and endometrial cancers, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• STRO-002 (STRO-002)

Snippet

Sponsor: Sutro Biopharma, Inc. | Conditions: Ovarian Cancer, Ovarian Carcinoma | Phase 1 | Status: COMPLETED